Characterization of autoantibodies to vasoactive intestinal peptide in asthma

Sudhir Paul, Sami I. Said, Austin Bassett Thompson, Deanna J. Volle, Devendra K. Agrawal, Hussein Foda, Santiago de la Rocha

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Vasoactive intestinal peptide (VIP) is a potent relaxant of the airway smooth muscle. In this study, VIP-binding autoantibodies were observed in the plasma of 18% asthma patients and 16% healthy subjects. Immunoprecipitation studies and chromatography on DEAE-cellulose and immobilized protein G indicated that the plasma VIP-binding activity was largely due to IgG antibodies. Saturation analysis of VIP binding by the plasma suggested the presence of one or two classes of autoantibodies, distinguished by their apparent equilibrium affinity constants (Ka). The autoantibodies from asthma patients exhibited a larger VIP-binding affinity compared to those from healthy subjects (Ka 7.8 × 109 M-1 and 0.13 × 109 M-1, respectively; P < 0.005). The antibodies were specific for VIP, judged by their poor reaction with peptides bearing partial sequence homology with VIP (peptide histidine isoleucine, growth hormone releasing factor and secretin). IgG prepared from the plasma of an antibody-positive asthma patient inhibited the saturable binding of 125I-VIP by receptors in guinea pig lung membranes (by 39-59%; P < 0.001). These observations are consistent with a role for the VIP autoantibodies in the airway hyperresponsiveness of asthma.

Original languageEnglish (US)
Pages (from-to)133-142
Number of pages10
JournalJournal of Neuroimmunology
Volume23
Issue number2
DOIs
StatePublished - Jul 1989

Fingerprint

Vasoactive Intestinal Peptide
Autoantibodies
Asthma
Antibodies
Healthy Volunteers
Immunoglobulin G
Peptide PHI
Vasoactive Intestinal Peptide Receptors
Immobilized Proteins
DEAE-Cellulose Chromatography
Growth Hormone-Releasing Hormone
Secretin
Sequence Homology
Immunoprecipitation
Smooth Muscle
Guinea Pigs
Lung
Peptides
Membranes

Keywords

  • Antibody affinity
  • Asthma
  • Vasoactive intestinal peptide autoantobody
  • Vasoactive intestinal peptide receptor

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Cite this

Characterization of autoantibodies to vasoactive intestinal peptide in asthma. / Paul, Sudhir; Said, Sami I.; Thompson, Austin Bassett; Volle, Deanna J.; Agrawal, Devendra K.; Foda, Hussein; de la Rocha, Santiago.

In: Journal of Neuroimmunology, Vol. 23, No. 2, 07.1989, p. 133-142.

Research output: Contribution to journalArticle

Paul, S, Said, SI, Thompson, AB, Volle, DJ, Agrawal, DK, Foda, H & de la Rocha, S 1989, 'Characterization of autoantibodies to vasoactive intestinal peptide in asthma', Journal of Neuroimmunology, vol. 23, no. 2, pp. 133-142. https://doi.org/10.1016/0165-5728(89)90032-5
Paul, Sudhir ; Said, Sami I. ; Thompson, Austin Bassett ; Volle, Deanna J. ; Agrawal, Devendra K. ; Foda, Hussein ; de la Rocha, Santiago. / Characterization of autoantibodies to vasoactive intestinal peptide in asthma. In: Journal of Neuroimmunology. 1989 ; Vol. 23, No. 2. pp. 133-142.
@article{a04e1420dbfa48e9bd99687928bcc2a4,
title = "Characterization of autoantibodies to vasoactive intestinal peptide in asthma",
abstract = "Vasoactive intestinal peptide (VIP) is a potent relaxant of the airway smooth muscle. In this study, VIP-binding autoantibodies were observed in the plasma of 18{\%} asthma patients and 16{\%} healthy subjects. Immunoprecipitation studies and chromatography on DEAE-cellulose and immobilized protein G indicated that the plasma VIP-binding activity was largely due to IgG antibodies. Saturation analysis of VIP binding by the plasma suggested the presence of one or two classes of autoantibodies, distinguished by their apparent equilibrium affinity constants (Ka). The autoantibodies from asthma patients exhibited a larger VIP-binding affinity compared to those from healthy subjects (Ka 7.8 × 109 M-1 and 0.13 × 109 M-1, respectively; P < 0.005). The antibodies were specific for VIP, judged by their poor reaction with peptides bearing partial sequence homology with VIP (peptide histidine isoleucine, growth hormone releasing factor and secretin). IgG prepared from the plasma of an antibody-positive asthma patient inhibited the saturable binding of 125I-VIP by receptors in guinea pig lung membranes (by 39-59{\%}; P < 0.001). These observations are consistent with a role for the VIP autoantibodies in the airway hyperresponsiveness of asthma.",
keywords = "Antibody affinity, Asthma, Vasoactive intestinal peptide autoantobody, Vasoactive intestinal peptide receptor",
author = "Sudhir Paul and Said, {Sami I.} and Thompson, {Austin Bassett} and Volle, {Deanna J.} and Agrawal, {Devendra K.} and Hussein Foda and {de la Rocha}, Santiago",
year = "1989",
month = "7",
doi = "10.1016/0165-5728(89)90032-5",
language = "English (US)",
volume = "23",
pages = "133--142",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Characterization of autoantibodies to vasoactive intestinal peptide in asthma

AU - Paul, Sudhir

AU - Said, Sami I.

AU - Thompson, Austin Bassett

AU - Volle, Deanna J.

AU - Agrawal, Devendra K.

AU - Foda, Hussein

AU - de la Rocha, Santiago

PY - 1989/7

Y1 - 1989/7

N2 - Vasoactive intestinal peptide (VIP) is a potent relaxant of the airway smooth muscle. In this study, VIP-binding autoantibodies were observed in the plasma of 18% asthma patients and 16% healthy subjects. Immunoprecipitation studies and chromatography on DEAE-cellulose and immobilized protein G indicated that the plasma VIP-binding activity was largely due to IgG antibodies. Saturation analysis of VIP binding by the plasma suggested the presence of one or two classes of autoantibodies, distinguished by their apparent equilibrium affinity constants (Ka). The autoantibodies from asthma patients exhibited a larger VIP-binding affinity compared to those from healthy subjects (Ka 7.8 × 109 M-1 and 0.13 × 109 M-1, respectively; P < 0.005). The antibodies were specific for VIP, judged by their poor reaction with peptides bearing partial sequence homology with VIP (peptide histidine isoleucine, growth hormone releasing factor and secretin). IgG prepared from the plasma of an antibody-positive asthma patient inhibited the saturable binding of 125I-VIP by receptors in guinea pig lung membranes (by 39-59%; P < 0.001). These observations are consistent with a role for the VIP autoantibodies in the airway hyperresponsiveness of asthma.

AB - Vasoactive intestinal peptide (VIP) is a potent relaxant of the airway smooth muscle. In this study, VIP-binding autoantibodies were observed in the plasma of 18% asthma patients and 16% healthy subjects. Immunoprecipitation studies and chromatography on DEAE-cellulose and immobilized protein G indicated that the plasma VIP-binding activity was largely due to IgG antibodies. Saturation analysis of VIP binding by the plasma suggested the presence of one or two classes of autoantibodies, distinguished by their apparent equilibrium affinity constants (Ka). The autoantibodies from asthma patients exhibited a larger VIP-binding affinity compared to those from healthy subjects (Ka 7.8 × 109 M-1 and 0.13 × 109 M-1, respectively; P < 0.005). The antibodies were specific for VIP, judged by their poor reaction with peptides bearing partial sequence homology with VIP (peptide histidine isoleucine, growth hormone releasing factor and secretin). IgG prepared from the plasma of an antibody-positive asthma patient inhibited the saturable binding of 125I-VIP by receptors in guinea pig lung membranes (by 39-59%; P < 0.001). These observations are consistent with a role for the VIP autoantibodies in the airway hyperresponsiveness of asthma.

KW - Antibody affinity

KW - Asthma

KW - Vasoactive intestinal peptide autoantobody

KW - Vasoactive intestinal peptide receptor

UR - http://www.scopus.com/inward/record.url?scp=0024392858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024392858&partnerID=8YFLogxK

U2 - 10.1016/0165-5728(89)90032-5

DO - 10.1016/0165-5728(89)90032-5

M3 - Article

C2 - 2542371

AN - SCOPUS:0024392858

VL - 23

SP - 133

EP - 142

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 2

ER -